Outline of patents

International Patent Reviews Releases Study on Sun Pharmaceuticals' LEVULAN® KERASTICK® patent

Retrieved on: 
Monday, July 26, 2021
Patent law, Pharmaceuticals policy, Monopoly, Patent, Pharmaceutical industry in China, United States patent law, Chemical patent, Articles, Outline of patents

DALLAS, July 26, 2021 /PRNewswire/ -- Today, International Patent Reviews, LLC (IPR) released a study on Sun Pharmaceuticals' U.S. Patent No.

Key Points: 
  • DALLAS, July 26, 2021 /PRNewswire/ -- Today, International Patent Reviews, LLC (IPR) released a study on Sun Pharmaceuticals' U.S. Patent No.
  • However, many pharmaceutical filings are purposefully structured to artificially extend the reach of protection afforded by our patent system."
  • IPR has developed a comprehensive and multifaceted process for identifying pharmaceutical patent filings that have taken advantage of the patent system.
  • The first patent for LEVULAN KERASTICK was issued in January of 1992.

ZYUS Life Sciences Strengthens Software Patent Portfolio Supporting Clinical Development

Retrieved on: 
Thursday, July 22, 2021
Other Health, Software, Research, General Health, Pharmaceutical, Data management, Technology, Clinical trials, Science, Biotechnology, Alternative medicine, Health, Intellectual property law, Software patent, United States Patent and Trademark Office, Patent, Outline of patents

ZYUS Life Sciences Inc. ("ZYUS"), a Canadian-based life sciences company leading scientific research and development in phyto-therapeutics, announced today that its wholly owned U.S. subsidiary, ZYUS Life Sciences U.S. Ltd. (ZYUS U.S.), has received one patent allowance notification and two patent issuances from the United States Patent and Trademark Office (USPTO).

Key Points: 
  • ZYUS Life Sciences Inc. ("ZYUS"), a Canadian-based life sciences company leading scientific research and development in phyto-therapeutics, announced today that its wholly owned U.S. subsidiary, ZYUS Life Sciences U.S. Ltd. (ZYUS U.S.), has received one patent allowance notification and two patent issuances from the United States Patent and Trademark Office (USPTO).
  • Advancement of these software patents will further strengthen ZYUS clinical trial program by ensuring access to proprietary clinical and healthcare technology solutions.
  • This technology can be used to, among other things, identify, recruit and track participants in clinical trials.
  • About ZYUS Life Sciences Inc.
    ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates.

Blue Biofuels Files 3 Additional Patents on its CTS Technology

Retrieved on: 
Wednesday, July 21, 2021
Intellectual property law, Monopoly, Patent, Patent law, United States patent law, Outline of patents

Alliance BioEnergy Plus Inc., DBA Blue Biofuels, (the Company) is pleased to announce that it filed 3 additional patents that follow on the granted patent to its Cellulose-to-Sugar (CTS) technology system.

Key Points: 
  • Alliance BioEnergy Plus Inc., DBA Blue Biofuels, (the Company) is pleased to announce that it filed 3 additional patents that follow on the granted patent to its Cellulose-to-Sugar (CTS) technology system.
  • In the process of testing and perfecting towards commercialization, the Company has developed additional unique technology related to its CTS system to file for the multiple additional patents.
  • These three patents are in addition to the primary granted patent and one other patent pending, making it five in total.
  • The patents show continuous technological achievement and development and ensures that the company is in full ownership of its core technology.

Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR

Retrieved on: 
Tuesday, July 13, 2021
Intellectual property law, Government, Countries, Patent law, United States patent law, Monopoly, Patent, Term of patent, Composition of matter, European Patent Convention, Outline of patents, Patent claim

The issuance of this Composition of Matter and Method of Use patent provides additional protection as MEDICE works towards the potential commercialization of ADAIR in the European Union and United Kingdom.

Key Points: 
  • The issuance of this Composition of Matter and Method of Use patent provides additional protection as MEDICE works towards the potential commercialization of ADAIR in the European Union and United Kingdom.
  • We are pleased to successfully expand our intellectual property portfolio with the issuance of this new European patent.
  • The new European patent covers composition of matter and method of use for ADAIR, with a base patent term extending until 2038.
  • ADAIR was previously granted two patents in the United States with a base patent term extending until 2037, excluding patent term extensions.

CytoDyn Granted a Significant Patent by USPTO for Methods of Treating Coronavirus Infection with Leronlimab

Retrieved on: 
Tuesday, July 6, 2021
Intellectual property law, International Searching and Preliminary Examining Authorities, Patent offices, Patent application, United States Patent and Trademark Office, Patent, United States patent law, Outline of patents

11,045,546 by the U.S. Patent and Trademark Office (USPTO) for methods of treating coronavirus infection (the Patent).

Key Points: 
  • 11,045,546 by the U.S. Patent and Trademark Office (USPTO) for methods of treating coronavirus infection (the Patent).
  • The Patent is owned by CytoDyn and its term of protection is expected to extend at least until June 15, 2040.
  • The USPTO prioritized examination of CytoDyns patent application, resulting in the grant of this Patent under the USPTOs COVID-19 Prioritized Examination Pilot Program in just about one (1) year.
  • The Patent discloses methods of treating hyperinflammationa common complication of COVID-19 caused by SARS-CoV-2 coronavirus infection.

Government of Canada announces new independent regulator for patent and trademark agents

Retrieved on: 
Monday, June 28, 2021
Legal professions, Intangible assets, Intellectual property law, Practice of law, Law, Law of the United Kingdom, Patent attorney, Trademark attorney, Trademark, Patent, Outline of patents, United States Patent and Trademark Office

Today, as part of the Government of Canada's first-ever Intellectual Property Strategy , the College of Patent Agents and Trademark Agents has been established to regulate the patent and trademark agent profession to ensure Canadians benefit from access to high-quality IP advice and services.

Key Points: 
  • Today, as part of the Government of Canada's first-ever Intellectual Property Strategy , the College of Patent Agents and Trademark Agents has been established to regulate the patent and trademark agent profession to ensure Canadians benefit from access to high-quality IP advice and services.
  • "The establishment of the College of Patent Agents and Trademark Agents marks an important milestone not only for our government's Intellectual Property Strategy but also for the entire patent and trademark profession.
  • Thomas Conway, Chair of the Board of Directors, College of Patent Agents and Trademark Agents
    "The publication of the College of Patent Agents and Trademark Agents Regulations marks the culmination of a 20-year journey towards self-regulation for the IP agent profession.
  • The College will also be responsible for maintaining the registers of patent agents and trademark agents, administering patent and trademark agent qualifying examinations, collecting associated College fees, and conducting investigations and disciplinary proceedings.

ProStar, the World Leader in Developing Precision Mapping Solutions®, Has Been Granted Another Major Canadian Patent

Retrieved on: 
Thursday, June 24, 2021
Patent law, Monopoly, Patent infringement, Prior art, Patent, Creativity, Business law, Mental processes, Outline of patents

"ProStar is a pioneer in precision utility locating, precision utility mapping, as well as digital management and distribution of utility information,"said Raymond R. Tabandeh, the LRRC partner who prosecuted the patent.

Key Points: 
  • "ProStar is a pioneer in precision utility locating, precision utility mapping, as well as digital management and distribution of utility information,"said Raymond R. Tabandeh, the LRRC partner who prosecuted the patent.
  • "This is ProStar's 20th issued patent and further buttresses ProStar's extensive U.S. and Canadian patent portfolio," added Tabandeh.
  • The patent is comprehensive and includes information about the topography of a region and the utilities located within the region.
  • Extensive patent services include: Patent Prosecution, Patent Litigation, Design Patents, International Patent Protection, Patent Opinions & Evaluations, Prior Art Searches & Evaluations, and PTAB Proceedings.

BioInvent receives notice of allowance in China for BI-1206 patent

Retrieved on: 
Thursday, June 24, 2021
Monopoly, Patent, Pharmaceutical industry in China, Outline of patents

This patent allowance is a strategic milestone in BioInvent's exclusive licensing agreement with CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China.

Key Points: 
  • This patent allowance is a strategic milestone in BioInvent's exclusive licensing agreement with CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China.
  • In 2020, CASI gained the rights for the development and commercialization of BI-1206 in mainland China, Taiwan, Hong Kong, and Macau.
  • Other patents in the same patent family have already been granted by the European Patent Office and in several other countries, including the US and Japan.
  • The company also has related patent applications pending in some countries.

BioInvent receives notice of allowance in China for BI-1206 patent

Retrieved on: 
Thursday, June 24, 2021
Monopoly, Patent, Pharmaceutical industry in China, Outline of patents

This patent allowance is a strategic milestone in BioInvent's exclusive licensing agreement with CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China.

Key Points: 
  • This patent allowance is a strategic milestone in BioInvent's exclusive licensing agreement with CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China.
  • In 2020, CASI gained the rights for the development and commercialization of BI-1206 in mainland China, Taiwan, Hong Kong, and Macau.
  • Other patents in the same patent family have already been granted by the European Patent Office and in several other countries, including the US and Japan.
  • The company also has related patent applications pending in some countries.

Rich Geruson, NexOptic Chairman, Announces NexOptic Receives its 2nd Patent Notice of Allowance from the US Patent Office for Another Key Artificial Intelligence Invention

Retrieved on: 
Thursday, June 17, 2021
Intellectual property law, Patent law, Patent, Outline of patents, Public participation in patent examination

A Notice of Allowance is an indication that the invention qualifies for a patent and that administrative and other steps are required prior to its issuance.

Key Points: 
  • A Notice of Allowance is an indication that the invention qualifies for a patent and that administrative and other steps are required prior to its issuance.
  • An invention is still considered patent pending until a final patent has been issued.
  • The patent, once issued, will provide additional key intellectual property protection for NexOptics disruptive AI for all levels of imaging including video, data compression and more.
  • NexOptic also reports that it continues to add additional in-house talent to its software team to support the development of its artificial intelligence program.